Big Pharma Split Corp.
PRM.TO · TSX
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | -CA$0 | CA$0 | CA$0 | CA$0 |
| % Growth | -221.8% | -33.9% | 54.8% | – |
| Cost of Goods Sold | CA$0 | CA$0 | CA$0 | CA$0 |
| Gross Profit | -CA$0 | CA$0 | CA$0 | CA$0 |
| % Margin | 100% | 79.1% | 85.4% | 100% |
| R&D Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| G&A Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| SG&A Expenses | CA$0 | CA$0 | -CA$0 | CA$0 |
| Sales & Mktg Exp. | CA$0 | CA$0 | CA$0 | CA$0 |
| Other Operating Expenses | CA$0 | -CA$0 | CA$0 | CA$0 |
| Operating Expenses | CA$0 | CA$0 | -CA$0 | CA$0 |
| Operating Income | -CA$0 | -CA$0 | CA$0 | CA$0 |
| % Margin | 133.6% | -202.4% | 134.9% | 24.9% |
| Other Income/Exp. Net | CA$0 | -CA$0 | -CA$0 | CA$0 |
| Pre-Tax Income | -CA$0 | -CA$0 | CA$0 | -CA$0 |
| Tax Expense | CA$0 | CA$0 | CA$0 | CA$0 |
| Net Income | -CA$0 | -CA$0 | CA$0 | -CA$0 |
| % Margin | 54.4% | -241.7% | 111.3% | -10.9% |
| EPS | -0.41 | -1.54 | 0.99 | -0.066 |
| % Growth | 73.4% | -255.6% | 1,604.6% | – |
| EPS Diluted | -0.41 | -1.54 | 0.99 | -0.066 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | CA$0 | CA$0 | CA$0 | CA$0 |
| Interest Expense | CA$0 | CA$0 | CA$0 | CA$0 |
| Depreciation & Amortization | CA$0 | CA$0 | CA$0 | -CA$0 |
| EBITDA | CA$0 | -CA$0 | CA$0 | -CA$0 |
| % Margin | -0% | -201.8% | 135.3% | -62.2% |